Iterum Therapeutics PLC ITRMF
0.00
0.00
NaN
as of 24 Sep
- Market cap
- $1.6M
- P/E
- 0.0×
Follow ITRMF
Insider Buys
alert about insiders buying in the last 12 month
| Older periods | Dec '24 | Mar '25 | Jun '25 | Sep '25 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
— | — | — | 0.00 |
P/S ratio |
— | — | — | 33.36 | |
P/FCF ratio |
— | — | — | 0.00 | |
P/Operating CF |
— | — | — | (4.12) | |
P/B ratio |
— | — | — | 0.00 | |
Price to Tangible BV |
— | — | — | 0.00 | |
EV/Sales |
— | — | — | 57.72 | |
EV/EBITDA |
— | — | — | 0.00 | |
EV/Operating CF |
— | — | — | (2.72) | |
EV/FCF |
— | — | — | (2.72) | |
Quick Ratio |
1.37 | 3.49 | 2.35 | 1.78 | |
Current Ratio |
1.41 | 3.72 | 2.69 | 2.13 | |
Net Debt/EBITDA |
1.35 | (2.54) | (1.47) | (1.38) | |
Debt/Assets |
45.52% | 62.79% | 60.72% | 65.27% | |
Debt/Equity |
(4.97) | (8.11) | (5.31) | (2.87) | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.04 | |
Operating CF/Net income |
0.65 | 0.63 | 0.73 | 0.83 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | (0.03) | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 323.33% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 1,664.36% | |
Intangible Assets out of Total Assets |
0.44 | 0.59 | 0.56 | 0.58 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 13.59% | |
Graham Net Nets |
— | — | — | (0.85) | |
Graham Number |
— | — | — | 1.65 | |
Earnings Yield |
— | — | — | (111.94%) | |
Free Cash Flow Yield |
— | — | — | (63.64%) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.01 | |
Operating CF per Share |
(0.22) | (0.09) | (0.12) | (0.16) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.22) | (0.09) | (0.12) | (0.16) | |
Cash per Share |
1.22 | 0.37 | 0.33 | 0.24 | |
Shareholders Equity per Share |
(0.21) | (0.07) | (0.10) | (0.16) | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
(0.21) | (0.07) | (0.10) | (0.16) | |
Free Cash Flow |
(4.26) | (3.06) | (4.75) | (7.46) | |
Working Capital |
7.18 | 9.89 | 9.36 | 7.30 | |
Capital Expenditures |
0.00 | 0.00 | 0.00 | (0.01) | |
Net Current Asset Value |
(23.89) | (22.02) | (23.01) | (26.16) | |
EV/EBIT |
— | — | — | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.03 | |
Net Profit Margin |
0.00% | 0.00% | 0.00% | (2,302.31%) | |
Price to Operating Income |
— | — | — | 0.00 | |
| Other line items | |||||
Average Receivables |
0.11 | — | — | 0.24 | |
Average Payables |
2.62 | 1.69 | 1.01 | 0.71 | |
Average Assets |
35.43 | 26.30 | 24.09 | 24.21 | |
Average Common Equity |
(5.24) | (4.35) | (7.40) | (9.44) |
Columns are period end dates